NCT06617897View on ClinicalTrials.gov

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

October 30, 2026

Conditions
Acquired Fibrinogen Deficiency
Interventions
BIOLOGICAL

CSL511 Fibrinogen concentrate (human)

CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.

BIOLOGICAL

Cryoprecipitate

Cryoprecipitate will be administered via IV infusion.

Trial Locations (1)

RG24 9NA

RECRUITING

Basingstoke and North Hampshire Hospital, Basingstoke

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY